Edwards Lifesciences (NYSE:EW) Sets New 1-Year High – Still a Buy?

Edwards Lifesciences Corporation (NYSE:EW) shares reached a new 52-week high on Thursday . The stock traded as high as $87.21 and last traded at $86.5270, with a volume of 1124743 shares traded. The stock had previously closed at $85.58.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 25th. Citigroup boosted their target price on Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. National Bankshares set a $92.00 target price on shares of Edwards Lifesciences in a report on Friday, October 31st. Finally, Oppenheimer cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Stock Up 0.3%

The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a 50-day moving average of $78.20 and a 200 day moving average of $77.72. The stock has a market capitalization of $50.11 billion, a price-to-earnings ratio of 12.42, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the firm posted $0.67 EPS. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 22,970 shares of company stock valued at $1,862,878 over the last 90 days. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

A number of large investors have recently bought and sold shares of the business. Brighton Jones LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $266,000. CWM LLC boosted its stake in Edwards Lifesciences by 36.3% during the first quarter. CWM LLC now owns 32,916 shares of the medical research company’s stock worth $2,386,000 after acquiring an additional 8,772 shares in the last quarter. Signaturefd LLC grew its holdings in Edwards Lifesciences by 11.5% in the first quarter. Signaturefd LLC now owns 6,202 shares of the medical research company’s stock worth $450,000 after purchasing an additional 638 shares during the period. Sigma Planning Corp increased its stake in Edwards Lifesciences by 4.9% in the first quarter. Sigma Planning Corp now owns 4,055 shares of the medical research company’s stock valued at $294,000 after purchasing an additional 191 shares in the last quarter. Finally, Apollon Wealth Management LLC increased its stake in Edwards Lifesciences by 8.9% in the first quarter. Apollon Wealth Management LLC now owns 7,916 shares of the medical research company’s stock valued at $574,000 after purchasing an additional 645 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.